KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals
08 November 2022 - 11:01PM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or
the “Company”), a leading medical technology company focused on
the development of innovative and easy-to-use subcutaneous infusion
solutions, today announced the progression of its agreement with
Kira Pharmaceuticals, including expansion into three important
additional indications.
Kira will utilize KORU Medical’s Freedom System for Phase II
studies of Kira’s lead program, KP-104, an innovative,
first-in-class bifunctional complement inhibitor, in three
indications. These diseases, collectively affecting over 150,000
patients in the United States and estimated hundreds of thousands
more globally, consist of nephrology conditions IgA Neuropathy
(IgAN) and Complement 3 Glomerulopathy (C3G) and hematology
condition Thrombotic Microangiopathy secondary to Systemic Lupus
Erythematosus (SLE-TMA). The expanded Kira partnership reflects the
previously announced collaboration with an unnamed partner for a
single hematology indication.
“We selected KORU Medical based on their track record of helping
patients receive high-value therapeutics subcutaneously in the
comfort of their home,” said Chaomei He, Kira’s Head of Chemistry,
Manufacturing, and Controls (CMC). “The Freedom System’s ease of
use, global regulatory approvals, experience with tens of thousands
of patients, and ability to rapidly enter the clinic gave us
confidence that KORU was the right partner for our KP-104
program.”
“We are privileged to work with Kira and help them achieve their
mission of helping patients living with complement-mediated disease
by providing treatment at home,” said Linda Tharby, KORU Medical’s
President and CEO. “The expansion of our work with Kira and
progression into Phase II studies is another important milestone in
our strategy to grow our novel therapies pipeline in multiple
therapeutic areas.”
About KORU Medical
KORU Medical develops, manufactures, and commercializes
innovative and easy-to-use subcutaneous infusion solutions that
improve quality of life for patients around the world. The FREEDOM
Syringe Infusion System (the “Freedom System”) currently includes
the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision
Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™.
These devices are used for infusions administered in the home and
alternate care settings. For more information, please visit
www.korumedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005213/en/
Investor Contact: Greg Chodaczek 347-620-7010
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024